Related Experiment Video

Updated: Jul 6, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Potential of tumour cells for delivering oncolytic viruses

Z Raykov1, J Rommelaere

  • 1Infection and Cancer Program, Abt. F010 and INSERM U701, German Cancer Research Centre, Heidelberg, Germany. z.raykov@dkfz.de

Gene Therapy
|March 22, 2008
PubMed

Insights

This review explores using tumor-derived carrier cells to improve oncolytic virus delivery for cancer treatment. These cell vehicles can act as virus factories and anticancer vaccines, enhancing therapeutic efficacy.

Area of Science:

  • Oncology
  • Immunotherapy
  • Virology

Background:

  • Tumor cells have been historically used as vaccines to stimulate the immune system against cancer.
  • Oncolytic viruses are emerging as potent cancer therapeutics due to their ability to selectively destroy tumor cells.
  • Current limitations in oncolytic virotherapy include poor delivery of viruses to primary and metastatic tumor sites.

Purpose of the Study:

  • To review strategies for overcoming oncolytic virus delivery limitations.
  • To propose novel methods for utilizing tumor-derived or transformed cells as delivery vehicles for oncolytic viruses.
  • To explore the dual role of these cell vehicles as virus factories and anticancer vaccines.

Main Methods:

  • Review of existing scientific literature on oncolytic virus delivery and cancer vaccines.
  • Analysis of strategies employing carrier cells for therapeutic delivery.
  • Proposal of novel therapeutic approaches based on current evidence.

Main Results:

  • Carrier cells, including tumor-derived and in vitro transformed cells, show potential for improving oncolytic virus delivery.
  • These cell vehicles can be engineered to act as localized "virus factories," enhancing viral spread within tumors.
  • The proposed strategies suggest a synergistic approach combining oncolytic virotherapy with cellular immunotherapy.

Conclusions:

  • Utilizing tumor-derived or transformed carrier cells offers a promising strategy to enhance oncolytic virus delivery and efficacy.
  • Cell vehicles can serve a dual purpose, acting as both delivery systems for oncolytic viruses and as components of an anticancer vaccine.
  • Further research into these cell-based delivery systems could significantly advance oncolytic virotherapy for cancer treatment.

More Related Videos

Ex Vivo Infection of Live Tissue with Oncolytic Viruses12:08

Ex Vivo Infection of Live Tissue with Oncolytic Viruses

Published on: June 25, 2011

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...